Primary aldosteronism, a common cause of severe hypertension 1 , features constitutive production of the adrenal steroid aldosterone. We analyzed a multiplex family with familial hyperaldosteronism type II (FH-II) 2 and 80 additional probands with unsolved early-onset primary aldosteronism. Eight probands had novel heterozygous variants in CLCN2, including two de novo mutations and four independent occurrences of a mutation encoding an identical p.Arg172Gln substitution; all relatives with early-onset primary aldosteronism carried the CLCN2 variant found in the proband. CLCN2 encodes a voltage-gated chloride channel expressed in adrenal glomerulosa that opens at hyperpolarized membrane potentials. Channel opening depolarizes glomerulosa cells and induces expression of aldosterone synthase, the rate-limiting enzyme for aldosterone biosynthesis. Mutant channels show gain of function, with higher open probabilities at the glomerulosa resting potential. These findings for the first time demonstrate a role of anion channels in glomerulosa membrane potential determination, aldosterone production and hypertension. They establish the cause of a substantial fraction of early-onset primary aldosteronism.
, the single largest cause of premature mortality 4 . About 6% of hypertensive patients in primary care have primary aldosteronism 1 , with higher frequencies among patients with severe hypertension. The plasma aldosterone level in primary aldosteronism is constitutively elevated despite low levels of the normal upstream regulator renin; hypokalemia is variable. Aldosterone-producing adrenal adenomas (APAs) and idiopathic hyperaldosteronism 5 are common causes of primary aldosteronism. Somatic mutations in KCNJ5, CACNA1D, ATP1A1 or ATP2B3 that cause increased glomerulosa cell Ca 2+ are sufficient for producing APAs [6] [7] [8] [9] [10] ; germline mutations alter CYP11B2 11 in glucocorticoid-remediable aldosteronism (GRA, also known as FH-I), KCNJ5 6, 12 in FH-III, CACNA1H 13 in FH-IV and CACNA1D 7 in PASNA syndrome 14 . These mutations define a common pathway for induction of aldosterone biosynthesisglomerulosa cell membrane depolarization activates voltage-gated Ca 2+ channels, which induces the rate-limiting enzyme for aldosterone biosynthesis, aldosterone synthase (encoded by CYP11B2), along with other enzymes in the biosynthetic pathway; increased mitochondrial Ca 2+ may also contribute 15 . In 1992, Stowasser et al. described a multiplex kindred featuring autosomal dominant primary aldosteronism that was clinically distinct from GRA, the only dominant syndrome then known, and hence called it FH-II 2 . The responsible gene in this kindred has not been identified. We recruited an additional affected individual of this kindred 2, 16 (family 3; Fig. 1 , Table 1 and Supplementary Note) and performed exome sequencing 13 of three affected subjects, identifying two shared novel protein-changing heterozygous variants in CLCN2 (chr. 3: g.184075850C> T (hg19), p.Arg172Gln, NP_004357) and LINGO1 (chr. 15: g.77906476G> C, p.His591Gln, NP_116197) (Supplementary Table 1 ). CLCN2 was considered the more likely candidate gene on the basis of conservation ( Fig. 1) , expression levels in human adrenal cortex (8.14 for CLCN2, 5.91 for LINGO1, log 2 scale, mean expression of all genes = 7.20 6 ) and segregation analysis in the pedigree ( Fig. 1 and Supplementary Table 2) .
We next searched for rare (allele frequency < 10 −5 in public databases) damaging 17 variants in CLCN2 and LINGO1 among the exomes of 35 unrelated individuals diagnosed with unsolved primary aldosteronism by age 10 years-an extreme phenotype 13 . Only CLCN2 showed such variants. All four were heterozygous and were absent in public databases (Supplementary Table 1) . Notably, one Letters NATurE GENETICs proband had the identical p.Arg172Gln variant found in family 3. In the three additional subjects, chr. 3: g.184076918A> T (p.Met22Lys) and chr. 3: g.184076907A> T (p.Tyr26Asn) occurred at positions conserved from invertebrates to humans and one variant produced a new splice donor site resulting in an in-frame deletion (chr. 3: g.184074782T> A, p.Lys362del) (Fig. 1) .
Analysis of CLCN2 in 45 additional unrelated subjects diagnosed with primary aldosteronism by age 20 years (Supplementary Table 3 ) identified two further occurrences of p.Arg172Gln (Fig. 1) . Additionally, chr. 3: g.184064498T> G (p.Ser865Arg) occurred at a moderately conserved position (Fig. 1) . Sanger sequencing confirmed all variants ( Supplementary Fig. 1 ). Sequencing of the Arg172 codon in 1,587 additional subjects referred for potential Mendelian hypertension, including 375 with primary aldosteronism diagnosed after age 20 years, identified no p.Arg172Gln variants, supporting enrichment of this variant in early-onset primary aldosteronism.
Among the four kindreds with p.Arg172Gln, the mutation was de novo in one kindred (kindred 318; absent in the proband's biological parents; Fig. 1 and Supplementary Table 4) . Among the other three kindreds, the maximum lengths of shared mutationlinked haplotypes between pairs of individuals ranged from 4,894 to 357,885 bp (Supplementary Table 5) , with the putative last shared ancestor occurring ~651 (95% confidence interval (CI), 203-2,615) to ~50,000 (95% CI, 10,000-infinity) generations ago 18 . Although extremely remote common ancestry is a possibility, independent occurrence is overwhelmingly likely. After finding this mutation in the first family, the probability of finding, by chance, three additional independent instances of the mutation encoding p.Arg172Gln (one de novo) among 80 probands is 6.5 × 10 −12 (Methods). The probability of any pair of these mutations being identical by descent from a remote common ancestor is even lower. Lastly, the burden of rare protein-altering CLCN2 variants in primary aldosteronism kindreds is significantly higher than in controls (8/81 versus 6/3,578,
, relative risk = 58.9; Supplementary Table 6) . Sanger sequencing identified eight carriers of the p.Arg172Gln variant in family 3 ( Fig. 1, Table 1 , Supplementary Fig. 1 and Supplementary Note). Seven carriers had an elevated aldosterone/ renin ratio (ARR; a screening test for primary aldosteronism); those tested had positive confirmatory fludrocortisone suppression tests (FSTs) and non-lateralizing aldosterone production. One subject had repeatedly normal ARR, suggesting incomplete penetrance. Subject 3-1, diagnosed with hypertension in her thirties and with primary aldosteronism at age 66 years, was wild type for CLCN2 (Supplementary Table 2 ). In addition to having later onset, she was distinct in having increased aldosterone with upright posture, typical of sporadic idiopathic hyperaldosteronism 5 . In kindred 1786, the proband's affected mother and brother carried the p.Arg172Gln variant. The brother had borderline ARR with suppressed renin and prehypertension at age 13 years. Subject 1492-1 was diagnosed with 
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hypertension and primary aldosteronism in infancy but became normotensive by age 2, suggesting variable expressivity with age. Among other probands, the mutation encoding the p.Met22Lys variant was de novo (Supplementary Table 4 ). Thus, in two of the four kindreds with parental data, the rare CLCN2 mutations were de novo. In silico splice-site analysis 19 of the variant in kindred 1492 predicted the creation of a new splice donor site at the end of exon 10, 3 bp upstream of the normal splice donor site. In a splicing assay in HEK cells (Supplementary Note), the wild-type exon was normally spliced but the mutation resulted exclusively in splicing at the predicted upstream site, producing an in-frame deletion of codon 362 ( Supplementary Fig. 1 ).
ClC-2, the chloride channel encoded by CLCN2, is found in many tissues, including brain, kidney, lung and intestine 20 . Additionally, CLCN2 RNA is found in the adrenal gland. Immunohistochemistry with an antibody specific for ClC-2 showed intense staining of human adrenal zona glomerulosa ( Fig. 2 and Supplementary Fig. 2 ), consistent with a role in regulating aldosterone production.
Chloride channels can conduct excitatory (membrane-depolarizing) chloride efflux or inhibitory influx, depending on the chloride gradient across the cell membrane. We determined the intracellular chloride concentration ([Cl - ] int ) in mouse adrenal gland slices (Fig. 3a,b and Supplementary Fig. 2 ) using fluorescence lifetime imaging microscopy (FLIM); the method is based on the concentration-dependent fluorescence quenching of a chloride-sensitive dye 21 . . All mutants shifted the activation curve to more positive voltages (Fig. 3, Supplementary Fig. 3 and Supplementary Table 8 ). ClC channels are homodimers, with each subunit forming a separate pore. Each of these conduction pathways can be individually opened and closed by a fast protopore gate, while a common slow gating mechanism acts on both pores 24, 26 . Whereas p.Ser865Arg slowed down deactivaton of both gates and altered the protopore open probability, all other variants modified the common gate by increasing its minimum open probability and accelerating its activation ( Fig. 3 and Supplementary Fig. 3 ). Mass spectrometry demonstrated that Ser865 was phosphorylated, suggesting a regulatory mechanism ( Supplementary Fig. 4 ). The observed gating alterations with the ClC-2 MUT channels predict significantly larger chloride efflux versus ClC-2 WT channels in glomerulosa cells at physiological membrane potentials.
To characterize the impact of the ClC-2 WT and ClC-2 MUT channels in human adrenal glomerulosa cells, we expressed these channels in human H295R adrenocortical cancer cells, an established model of aldosterone production 27 . Confocal microscopy showed partial colocalization of YFP-tagged ClC-2 WT and ClC-2 MUT with a cell surface membrane marker; the Met22Lys variant showed less colocalization than ClC-2 WT ( Supplementary Fig. 4 ). RNA-seq ( Fig. 4a and Supplementary Table 9) demonstrated that transfection MUT produced significantly greater increases in CYP11B2 expression than were observed with CLCN2 WT (Fig. 4b ). In contrast, transfection with CLCN2 encoding loss-of-function mutations 30 did not change CYP11B2 expression ( Supplementary Fig. 5 ). H295R cells and their subclone HAC15 have negative membrane potentials 31 . Current-clamp recordings demonstrated significant depolarization of HAC15 cells upon expression of wild-type ClC-2; the p.Arg172Gln substitution amplified this effect (Fig. 4c) .
The finding of four independent occurrences of p.Arg172Gln (one de novo), along with four additional novel variants (one de novo), among 81 probands with early-onset primary aldosteronism provides strong evidence implicating these variants in disease pathogenesis. The localization of ClC-2 in adrenal zona glomerulosa is consistent with this observation. The electrophysiological impact of mutant channels and their effects on aldosterone synthase expression demonstrate that the corresponding mutations cause gain of function, producing membrane depolarization and increasing CYP11B2 expression (Fig. 4d) . Because the syndrome in family 3 was named FH-II 2 , we suggest using this term for patients with germline CLCN2 variants.
Retrospectively, efforts to map the disease-causative gene in family 3 32 were challenged by a phenocopy (sporadic idiopathic hyperaldosteronism) in subject 3-1, incomplete penetrance and phenotypic uncertainty. Rare CLCN2 variants explained primary aldosteronism in ~10% of individuals in the early-onset cohort studied, suggesting that there are likely additional causative genes yet undiscovered. Genetic testing for germline mutations in CLCN2 and other genes involved in early primary aldosteronism can be useful for establishing diagnosis, defining treatment options and assessing risk to future offspring. 
Letters
NATurE GENETICs
Probands with FH-II showed early-onset primary aldosteronism and hypertension, often with hypokalemia. Hypertension was controlled with mineralocorticoid receptor antagonists or other antihypertensives (Supplementary Note). This phenotype appears indistinguishable from that of patients with CACNA1H mutations 13 . Hybrid steroid production and/or response to glucocorticoids, historically used to diagnose GRA 11 , was absent, as were massive adrenal hyperplasia (present in many subjects with KCNJ5 variants 6, 12 ) and neurodevelopmental abnormalities (characteristic of subjects with CACNA1D mutation 7 ). Despite widespread CLCN2 expression, subjects with gain-of-function CLCN2 variants shared no apparent pathology other than primary aldosteronism, whereas loss-offunction CLCN2 variants cause leukoencephalopathy with ataxia 33 , with a similar phenotype in mice 34 . Incomplete penetrance or phenotypic amelioration with age, as sometimes occurs with germline mutations in CYP11B2, KCNJ5, CACNA1D and CACNA1H 7,12,13,35 , occurred in some subjects with CLCN2 mutations.
Our findings implicate the activity of an anion channel in the regulation of aldosterone biosynthesis, primary aldosteronism and hypertension. Whether previously described slowly activating tiny chloride currents at strongly negative voltages in rat glomerulosa cells 15 or Ras-dependent chloride currents 36 represent ClC-2 activity is unclear. In vivo, ClC-2 may contribute to hyperpolarization-induced depolarization of adrenal glomerulosa cells, cyclic membrane potential oscillations and aldosterone production 22 . Variants implicated in primary aldosteronism would likely amplify these effects. Mouse models may prove useful to study such effects.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41588-018-0048-5. IL8  CD97  KIRREL3  KCTD15  WSCD1  B3GNT7  SNAP91  RGS4  ICA1  RPS6KL1  EPPK1  LINC00282  CCDC83  VEPH1  CLEC4M  GPR126  LOC113230  CABLES1   TLX1  C1QTNF6  GALNT5  SQRDL  EIF5AL1  RPLP0P2  HCRTR2  MIR17HG  ACTG2  LUZP2  VIPR1  DNAJC15  SPTSSB  IGFBP4  HSPA6  PCDP1  MNX1  SLC6A17  CENPV  PCSK1  SCN1B  ACHE  ADAM19   FOS  KAZN  GRM8  MFI2  TIMP4  VGLL2  MICB  KCNK12  PTGS1  CLCN2  HSPB7  SNAR-E  CYP11B2  ARID5A  EMX2  CCDC169-SOHLH2   TPPP3  NR4A2  HRC  MYOM1  PRKCH  RAPGEF4   MC2R  NID2  TRPM4  INHBE  CACNA1C   SCG2  ETV4  CYP11B1  SCGB2A2   SELM  TRIB1  VDR  SDC1  CD79A  SPINK5  ISM1  ST6GALNAC3   TFPI2  GPC4  ID1  COL25A1   LBH  RNASE4  CCDC136  NDRG4  NUPR1  TINAGL1  PGM2L1 Table 8 for statistical analysis). c, Resting membrane potential (plots as in b) of HAC15 cells stably expressing CLCN2 (WT or Arg172Gln) and untransfected controls. WT and Arg172Gln channels cause significant depolarization versus the control, and Arg172Gln causes significant depolarization versus WT channels (see Supplementary Table 8 for statistical analysis and tests used). d, Model of ClC-2 function in human adrenal glomerulosa. Resting cells are hyperpolarized. Ang II and hyperkalemia cause depolarization, activation of voltage-dependent calcium channels, calcium influx and increased CYP11B2 expression via the transcription factor NR4A2 (NURR1). ClC-2 MUT causes increased CYP11B2 expression by membrane depolarization via increased chloride efflux. **P < 0.01; ***P < 0.001; ****P < 0.0001. , 35 unrelated primary aldosteronism subjects without known disease-causing mutations, diagnosed by age 10 years (clinical characteristics published 13 ), and 45 subjects diagnosed with primary aldosteronism by age 20 years (Supplementary Table 3 ). Selected families had additional members recruited. Controls were 3,578 unaffected parents of autistic offspring 38 . Research protocols were approved by local institutional review boards at Yale University and the University of Queensland, and all probands and family members provided informed consent. Primary aldosteronism was diagnosed on the basis of elevated ARR (> 20 ng/dl:ng/ml/h or equivalent values) 5 with aldosterone > 15 ng/dl or marginally elevated values in the presence of hypokalemia. Confirmatory testing was performed according to the referring centers' guidelines 5 . Venous blood or saliva samples were obtained from subjects and family members and subjected to exome and/or Sanger sequencing 13 . DNA preparation and exome sequencing. DNA was prepared from venous blood or saliva samples using standard procedures. Exome capture was performed using the 2.1M NimbleGen Exome reagent (Roche NimbleGen), and 75-bp paired-end sequencing was performed on the Illumina platform with analysis performed as described 13 .
Sanger sequencing of genomic DNA and genotyping of parent-offspring trios. Direct bidirectional Sanger sequencing of candidate variants from genomic DNA of the indicated subjects was performed at Beckman Coulter Genomics or the Keck DNA sequencing facility at Yale University following PCR amplification. Rare variants identified in index cases through exome sequencing were genotyped by targeted PCR and Sanger sequencing in both parents to confirm paternity/maternity.
Immunohistochemistry and immunofluorescence.
Formalin-fixed, paraffinembedded 5-µ m human adrenal gland sections were obtained from US Biomax and Pantomics. Immunohistochemistry was performed as described 7 , with the exception that 10% donkey serum was used for blocking. The concentration of the antigenic peptide was 0.4 mg/ml, and 1 µ g of peptide per microgram of antibody was used. Images were recorded on a Zeiss Axioplan 2 Imaging microscope (10× and 40× objectives) with a Zeiss AxioCam Mrc5 camera. Image cropping was performed in Adobe Illustrator CS4. The primary antibody against ClC-2 was HPA014545 (Sigma-Aldrich Prestige Antibodies; 1:100 dilution, incubation overnight at 4 °C), and the antibody against Dab2 was sc-13982 (Santa Cruz Biotechnology; 1:100 dilution). The secondary antibody was donkey antirabbit antibody (Jackson, 035-152, 1:200 dilution, incubation for 2 h at room temperature) for human samples. To confirm selection of the zona glomerulosa in mouse adrenal slices for FLIM, slices were stained with the antibody to Dab2 (1:100 dilution, incubation overnight at 4 °C). The secondary antibody was donkey anti-rabbit antibody conjugated to Alexa Fluor 647 (A-31573, Thermo Fisher Scientific, 1:1,000 dilution, incubation for 2 h at room temperature). Immunofluorescence images were recorded on a Leica TCS SP5 laser scanning confocal microscope (Leica Microsystems).
Molecular cloning.
Site-directed mutagenesis (QuikChange, Agilent Technologies) was performed to introduce mutations into pcDNA5/FRT/TO ClC-2 24 according to the manufacturer's instructions. Primer sequences (M22K_F/_R, Y26N_F/_R, R172Q_F/_R, K362 del new_F/_R) are given in Supplementary Table 10 . Each construct was validated by sequencing of the entire coding region. Mutant cDNAs were subcloned in frame into the pRcCMV vector containing YFP cDNA with NotI and PmlI for use in confocal microscopy only. Two independent clones were assessed in all experiments (Supplementary Fig. 3 ).
Generation of stable cell lines. Stable HEK293 cell lines were generated using the Flp-In T-REx system (Invitrogen, Life Technologies) according to the manufacturer's instructions. HEK293 cells do not express HEPACAM (Human Protein Atlas; see URLs). Flp-In T-REx 293 cells (authenticated, Eurofins Genomics) were cultured in high-glucose DMEM (Biochrom) with 10% FBS (Biochrom), 1% penicillin-streptomycin, 100 µ g/ml zeocin and 15 µ g/ ml blasticidin (all Invitrogen) at 37 °C and 5% CO 2 in a humidified atmosphere. Cells were transfected with 2.4 µ g of pcDNA5/FRT/TO + insert (CLCN2 mutants: p.Met22Lys, p.Tyr26Asn, p.Arg172Gln, p.Lys362del, p.Ser865Arg; two clones each) and 21.6 µ g of pOG44 using Lipofectamine 2000 (Invitrogen) and OptiMEM (Gibco by Life Technologies). The following day, the medium was changed to highglucose DMEM supplemented with 10% Tet-free FBS (Gibco) and 1% penicillinstreptomycin. 48 h after transfection, cells were split onto 15-cm dishes and selected with 15 µ g/ml blasticidin and 150 µ g/ml hygromycin (Invitrogen). Single colonies were selected. Variants were confirmed by Sanger sequencing of DNA extracted from stable cell lines, and inducible expression was verified by western blot (ClC-2 antibody, ACL-002, Alomone Labs).
The HAC15 cell line was kindly provided by W. Rainey (University of Michigan), authenticated by short tandem repeat (STR) analysis (ATCC Cell Line Authentication Service) and cultured in DMEM/F12 (GlutaMAX, Gibco) supplemented with 5% HyClone Cosmic Calf Serum (CCS; GE Healthcare Life Sciences), 1% penicillin-streptomycin (Gibco), 1% insulin transferrin selenium (ITS; Gibco), 1% MEM Non-Essential Amino Acids Solution (Gibco) and 0.1% CD Lipid Concentrate (Gibco) at 37 °C and 5% CO 2 in a humidified atmosphere. Stable cell lines were prepared using the Piggybac transposon system (System Biosciences). cDNAs of CLCN2 (wild type and encoding p.Arg172Gln) were subcloned into pENTR-2B-Dual using NotI and XhoI. Gateway LR recombination (Invitrogen) was performed with pPiggybac-EF1 Neo and pTF rLTA (a kind gift of C. Gomez-Sanchez, University of Mississippi). Inserts were verified by Sanger sequencing. HAC15 cells were transfected using an Amaxa Nucleofector I (Lonza; 2 million cells, 2 µ g of plasmid DNA, 0.8 µ g of Super Piggybac transposase; program X-005). After 48 h, selection was initiated by addition of 5 µ g/ml blasticidin (Gibco) to the growth medium. Inducible expression was verified by western blot (ClC-2 antibody, ACL-002) after incubation with 1 µ g/ml doxycycline (Sigma-Aldrich) for 24 h.
Preparation of acute adrenal slices. After anesthetizing mice with isoflurane and decapitation, both adrenal glands were rapidly removed and placed in ice-cold bicarbonate-buffered saline (BBS) (125 mM NaCl, 2 mM KCl, 26 mM NaHCO 3 , 0.1 mM CaCl 2 , 5 mM MgCl 2 , 10 mM glucose, constantly oxygenated with 5% CO 2 in O 2 ) for the removal of surrounding fat. The adrenal glands were embedded in 4% agarose in BBS, mounted, cut at 4 °C (150-200 µ m thick) with a Microm HM 650V (Thermo Scientific; frequency 60 Hz, amplitude 1 mm, drive 10) and held at 35 °C for 30 min in BBS. Slices were subsequently stored in BBS at 37 °C for further experiments. During each experiment, slices were constantly perfused with solution at 37 °C, and all measurements were completed within 8 h of organ removal.
Fluorescence lifetime imaging microscopy. Prior to chloride imaging experiments, adrenal slices were incubated in BBS containing 10 mM MQAE (Sigma-Aldrich) 39 for 45-60 min at room temperature. Slices were transferred to an imaging chamber and perfused with BBS solution containing 2 mM instead of 0.1 mM Ca
2+
; FLIM was performed as described 21 . The solution was perfused through a heating coil, resulting in a temperature of 37 °C in the perfusion chamber. Fluorescence was stimulated by two-photon excitation (λ exc = 750 nm). MQAE fluorescence was filtered (short-pass filter 500 nm, λ obs < 510 nm; Omega Optical), and mean fluorescence lifetimes were measured using multidimensional time-correlated single-photon counting (TCSPC). TCSPC electronics (SPC-152, Becker & Hickl) and acquisition software were used for FLIM as described 40 . We recorded data for 12 slices from five different C57BL/6 mice (two male, three female) of age 3 months or older. 
] int could then be calculated according to this relationship. The three outermost cell layers were assumed to form the zona glomerulosa based on their characteristic nucleus-to-cytoplasm ratio and the corresponding staining with antibody to DAB2 (sc-13982, Santa Cruz Biotechnology) performed separately. Each cell was defined as a region of interest (ROI) with the exclusion of the nucleus, and fluorescence lifetimes were determined as mean values of the average fluorescence lifetimes of all pixels in a given ROI. Fluorescence lifetimes were calculated using SPCImage 5.6 (Becker & Hickl) and exported for further extraction in Fiji. Statistical analysis was performed using SigmaPlot 12 (Systat) and Python 3.5.2 + numpy 1.12.1 + scipy 0.18.1 + pandas 0.19.2 + seaborn 0.7.1 using built-in functions. The FLIM datasets generated or analyzed during the current study are available on request. Python scripts for analysis are based on built-in functions of the above-mentioned packages but are available on request.
Electrophysiological recordings. Flp-In T-REx stable cell lines were used for electrophysiological recordings. For each construct, at least two clones from at least two separate preparations were included in the analysis. To avoid chloride depletion at large current amplitudes 
Instantaneous current amplitudes at the fixed tail step to + 60 mV were normalized and plotted against the preceding voltage step to show relative open probability curves. The durations of the voltage steps were 5 s for ClC-2 WT and ClC-2 Ser865Arg and 1 s for all other mutants, so that steady-state open probabilities were determined. Open probabilities (P open ) were fitted using a modified Boltzmann equation
to allow for a comparison of the half-maximal activation (V 1/2 ). Fitting of the activation and deactivation current traces with the sum of two exponential functions revealed fast (τ 1 ) and slow (τ 2 ) time constants, respectively.
ClC chloride channels are double-barreled channels with two conduction pathways. Protopores can be individually opened and closed by a fast gating process, but also jointly by slow common gating. Under the assumption that protopore and common gating processes are independent, the overall open probability equals the product of the respective individual open probabilities 43 .
By inserting a 15-ms pulse to -220 mV between the variable test pulse and the tail pulse, the ClC-2 fast gate is maximally opened (P fast = 1) 44 , and the common gate open probability can be determined. Fast protopore gate open probabilities were calculated by dividing the overall open probability by the common gate open probability.
Resting potentials in untransfected or induced (1 µ g tetracycline/ml medium for 24 h) stably transfected HAC15 cells were measured using the perforated patch technique 45 , we included the poreforming, monovalent-cation-selective antibiotic gramicidin D (Sigma-Aldrich) in the pipette solution to obtain access to the inside of the cell 45 . Gramicidin stock solution (50 mg/ml in DMSO) was prepared daily, and the diluted solution (final concentration of 100 µ g/ml) was prepared every 2 h. The tip of the pipette (open resistance of 1.5-3 MΩ ) was filled with solution lacking gramicidin to facilitate gigaseal formation. Break-in was typically observed after 15-45 min. Resting potentials were determined using a HEKA EPC-10 patch-clamp amplifier and PatchMaster software (HEKA Elektronik) from the mean of 10-to 60-s voltage recording segments with the current clamped to 0 pA. Only cells that exhibited ClC-2-like currents (visible slow activation upon hyperpolarization and a current larger than 40 pA at -160 mV in subsequent voltage-clamp experiments) were used for analysis.
Analysis of all electrophysiological experiments was performed using FitMaster software (HEKA Elektronik), SigmaPlot 12 (Systat) and Python 3.5.2 + numpy 1.12.1 + scipy 0.18.1 + pandas 0.19.2 using built-in functions. The electrophysiology datasets generated or analyzed during the current study are available on request. Python scripts for analysis are based on built-in functions of the above-mentioned packages but are available on request. Normality was assessed by Shapiro-Wilk test.
Culture of H295R cells. H295R human adrenocortical cells (a kind gift of M. Haase, Heinrich Heine University) were authenticated by STR analysis (ATCC Cell Line Authentication Service) and cultured in DMEM/F12 supplemented with HEPES (Gibco), 2.5% Ultroser G (Pall), 1% ITS (Corning) and 1% penicillinstreptomycin (Gibco) at 37 °C and 5% CO 2 in a humidified atmosphere.
Quantitative real-time PCR. Three million H295R cells were resuspended in 100 µ l of Nucleofector solution R (Lonza) plus 3 µ g of plasmid DNA (pcDNA/FRT/TO empty vector, wild-type or mutant CLCN2) and electroporated with program P-20 using an Amaxa Nucleofector I (Lonza). After recovering the cells in RPMI-1640 medium (Gibco) for 15 min at 37 °C, cells were plated on 12-well plates. 24 h after transfection, H295R cells were starved in DMEM/F12 supplemented with HEPES, 0.1% Ultroser G and 1% penicillin-streptomycin for an additional 24 h. Total RNA was isolated using the RNeasy Mini kit (Qiagen) and quantified with a Nanodrop 2000 (Thermo Scientific). After reverse transcription of RNA using the QuantiTect reverse transcription kit (Qiagen), TaqMan gene expression assays (Applied Biosystems) for GAPDH (Hs02758991_g1) as a housekeeping gene and CYP11B2 (Hs01597732_m1) as the gene of interest were performed using TaqMan Gene Expression Master Mix. Each variant was assessed in parallel with empty vector control or vector expressing wild type. Gene expression was evaluated relative to the housekeeping gene and expressed as 2
ΔΔCt
. Normality was assessed by ShapiroWilk test. Statistical differences were assessed by ratio-paired two-tailed t tests (for normally distributed individual data), one-way ANOVA (for normally distributed multiple comparisons; adjusted P value reported) or Friedman test (multiple comparisons, no normal distribution; adjusted P value reported) in GraphPad Prism 7.
Whole-transcriptome sequencing, read alignment and differential gene expression analysis. H295R cells were transfected in two independent reactions as above, and RNA was isolated using TRIzol (Thermo Fisher Scientific) followed by DNase digestion and column purification (RNeasy, Qiagen). Libraries were prepared after poly(A) selection. Samples were sequenced on the Illumina HiSeq 2500 instrument at the Yale Center for Genome Analysis, producing a mean of 47.9 million 75-bp single-end reads. The quality of the raw sequencing reads was evaluated using FastQC version 0.10.4 (see URLs), and the base of lower quality (base quality score < 20) in the last position was trimmed. TopHat v2.1.1 46 was used to align the high-quality sequencing reads to reference human genome sequence build hg19. Differentially expressed genes were identified by Cuffdiff v2.2.1 47 . An FDR-adjusted P value (q value) ≤ 0.05 and |log 2 (fold change)| ≥ 1 were set as the cutoffs for significant differential expression.
Estimation of the probability of observing one de novo and two transmitted p.Arg172Gln variants in CLCN2. From the identification of the novel p.Arg172Gln variant in family 3, we calculated the probability of finding an identical de novo mutation and two independent instances of the same transmitted variant by chance among 80 probands. Using the genome-wide mutation rate of 1.67 × 10 −8 mutations per base per generation from a recent study 48 , we estimated that the probability of seeing any specific de novo mutation in one individual is 3.34 × 10 −8 . For transmitted events, we applied the UnseenEst 49 algorithm to estimate the probability of finding an unseen missense mutation in human populations. A total of 33,778 healthy individuals were selected from the ExAC database 50 to match the population distribution of the 2010 US Census. The US Census-matched dataset was trained in the UnseenEst 49 algorithm to estimate the frequency distribution of distinct unseen missense mutations for the US population. The predicted frequency distribution was used to extrapolate the probability of observing one unseen transmitted event (probability = 2.81 × 10
−5
). Taken together, the probability of observing one de novo and two transmitted p.Arg172Gln variants among 80 independent samples is estimated as follows. Shared haplotypes and estimation of the age of the mutation encoding p.Arg172Gln in CLCN2. Genotypes of SNPs flanking the CLCN2 Arg172Gln mutation were extracted from exome data. To estimate the age of the mutation in CLCN2 encoding p.Arg172Gln testing the assumption that the mutation is identical by descent among each possible pair of kindreds with the variant (except the documented de novo mutation), we used the ESTIAGE algorithm to estimate the pairwise time of coalescence for the three pairs of kindreds as previously described 13, 18 . ESTIAGE uses a maximum-likelihood approach to estimate the mutation age, which takes into account the frequencies of the shared allele at each marker and the recombination fractions between the mutation of interest and polymorphic markers located within or at the boundaries of the shared haplotype. Seventeen polymorphic markers spanning the shared haplotype were used for input (Supplementary Table 5 ). The marker allele frequencies were estimated from the Finnish and non-Finnish European populations in the ExAC database 50 , and the mutation rate was set to 2 × 10 
Data exclusions
Describe any data exclusions. For electrophysiological recordings (technically acceptable recording, presence of ClC-2-like currents) and FLIM (outer layers of the adrenal gland as described in Methods) experiments, only inclusion criteria were defined with no data being excluded afterwards. For CYP11B2 qPCR ( Figure 4C ), the first transfection was excluded because the experimentator performed this protocol and transfection (via electroporation) for the first time and used it for practice. For confocal microscopy, cells without sufficient detection of CFP and/or YFP were excluded. For membrane potential measurements, cells without ClC-2-like currents were excluded.
Replication
Describe whether the experimental findings were reliably reproduced.
Electrophysiological experiments, FLIM data, real-time PCRs, and confocal microscopy were performed using multiple separate preparations and at least two DNA or stable cell line clones and were reliably reproduced. IHC was reliably reproduced (2 technical replicates each of two biological replicates). Splicing assay was performed using two independent clones with indistinguishable results. Mass spectrometry was performed on two independent preparations, with reproducible results. Similar results were obtained from two preparations using a different solvent.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Samples for electrophysiological, FLIM experiments, confocal microscopy, IHC and real-time PCRs were not randomized.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
For electrophysiological, FLIM and RNA sequencing experiments, investigators were not blinded to group allocation. For CYP11B2 qPCR ( Figure 4C ) the investigator was blinded to group allocation of two replicates by replacing the plasmid names with numbers. The investigator was not blinded to group allocation for confocal microscopy and immunohistochemistry.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
There are restrictions on availability of subject DNAs and exome sequencing data because of a lack of consent for data sharing and potential identification of subjects from exome data.
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
Anti-CLCN2 (HPA014545): Sigma-Aldrich; Lot # R06751; polyclonal; IgG; validation is described in human protein atlas (http://www.proteinatlas.org/ ENSG00000114859-CLCN2/antibody) Dab2 (H-110): Santa Cruz sc-13982; Lot # E3013; polyclonal; validation is described in the following citations: PMID: # 24889971, PMID: # 23293299, PMID: # 23840954
